These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9232443)

  • 1. Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection.
    Reinke P; Schwinzer H; Höflich C; Ode-Hakim C; Döcke WD; Frei U; Volk HD
    Immunol Lett; 1997 Jun; 57(1-3):151-3. PubMed ID: 9232443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of peripheral blood T-lymphocytes in kidney transplant recipients treated with low dose OKT3 therapy.
    Galante NZ; Câmara NO; Kallás EG; Salomão R; Pacheco-Silva A
    Immunol Lett; 2004 Jan; 91(1):75-7. PubMed ID: 14757373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
    Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY
    Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis.
    Herbelin A; Abramowicz D; de Groote D; Naret C; Kreis H; Bach JF; Goldman M; Chatenoud L
    Transplantation; 1999 Sep; 68(5):616-22. PubMed ID: 10507478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action and overview of OKT3.
    Norman DJ
    Ther Drug Monit; 1995 Dec; 17(6):615-20. PubMed ID: 8588230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
    Wilde MI; Goa KL
    Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice.
    Wissing KM; Desalle F; Abramowicz D; Willems F; Leo O; Goldman M; Alegre ML
    Transplantation; 1999 Sep; 68(5):677-84. PubMed ID: 10507488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 first-dose reaction: association with T cell subsets and cytokine release.
    Gaston RS; Deierhoi MH; Patterson T; Prasthofer E; Julian BA; Barber WH; Laskow DA; Diethelm AG; Curtis JJ
    Kidney Int; 1991 Jan; 39(1):141-8. PubMed ID: 1900552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
    Wissing KM; Morelon E; Legendre C; De Pauw L; LeBeaut A; Grint P; Maniscalki M; Ickx B; Vereerstraeten P; Chatenoud L; Kreis H; Goldman M; Abramowicz D
    Transplantation; 1997 Oct; 64(7):999-1006. PubMed ID: 9381549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro.
    Choi I; De Ines C; Kürschner T; Cochlovius B; Sörensen V; Olafsen T; Sandlie I; Little M
    Eur J Immunol; 2001 Jan; 31(1):94-106. PubMed ID: 11169443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
    J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
    Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of T cell associated surface antigen density changes during OKT3 therapy of renal allograft rejection.
    Shabtai M; Waltzer WC; Dominguez-Rafer C; Pullis CK; Malinowski K; Raisbeck AP; Rapaport FT
    J Urol; 1991 May; 145(5):928-31. PubMed ID: 1901920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
    Chatenoud L; Ferran C; Legendre C; Thouard I; Merite S; Reuter A; Gevaert Y; Kreis H; Franchimont P; Bach JF
    Transplantation; 1990 Apr; 49(4):697-702. PubMed ID: 2109379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.